NanoMosaic develops advanced diagnostic tools for early illness detection and biomarker identification using nanoscale technology. Their solutions enable healthcare providers to monitor patient prognostics more accurately, improving early intervention and treatment outcomes.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional diagnostic methods for early disease detection often lack the sensitivity to identify subtle changes at the molecular level, hindering timely intervention and personalized treatment strategies. Current biomarker identification techniques can be slow, costly, and require large sample volumes, limiting their applicability in routine clinical settings.
Solution
NanoMosaic is developing a platform for high-sensitivity protein and nucleic acid analysis, enabling earlier and more accurate disease detection. Their technology leverages nanoscale engineering to amplify signals from low-abundance biomarkers, providing a comprehensive molecular profile from minimal sample volumes. This approach facilitates the identification of novel biomarkers and the development of more effective diagnostic assays. The platform aims to improve patient outcomes by enabling proactive disease management and personalized treatment decisions.
Target Audience
The primary target audience includes clinical laboratories, pharmaceutical companies, and research institutions involved in diagnostic development and personalized medicine.
Features
- Nanoscale architecture for enhanced signal amplification of target molecules
- Multiplexed analysis of proteins and nucleic acids from a single sample
- High-throughput screening capabilities for biomarker discovery
- Automated sample processing and data analysis workflows
- Compatibility with various sample types, including blood, plasma, and tissue